

# $\beta$ -Catenin Promotes Regulatory T-cell Responses in Tumors by Inducing Vitamin A Metabolism in Dendritic Cells

Yuan Hong<sup>1</sup>, Indumathi Manoharan<sup>1</sup>, Amol Suryawanshi<sup>1</sup>, Tanmay Majumdar<sup>1</sup>, Melinda L. Angus-Hill<sup>2</sup>, Pandelakis A. Koni<sup>1,3</sup>, Balaji Manicassamy<sup>4</sup>, Andrew L. Mellor<sup>1,3</sup>, David H. Munn<sup>1,5</sup>, and Santhakumar Manicassamy<sup>1,3</sup>

## Abstract

Tumors actively suppress antitumor immunity, creating formidable barriers to successful cancer immunotherapy. The molecular mechanisms underlying tumor-induced immune tolerance are largely unknown. In the present study, we show that dendritic cells (DC) in the tumor microenvironment acquire the ability to metabolize vitamin A to produce retinoic acid (RA), which drives regulatory T-cell responses and immune tolerance. Tolerogenic responses were dependent on induction of vitamin A-metabolizing enzymes via the  $\beta$ -catenin/T-cell factor (TCF) pathway in

DCs. Consistent with this observation, DC-specific deletion of  $\beta$ -catenin in mice markedly reduced regulatory T-cell responses and delayed melanoma growth. Pharmacologic inhibition of either vitamin A-metabolizing enzymes or the  $\beta$ -catenin/TCF4 pathway *in vivo* had similar effects on tumor growth and regulatory T-cell responses. Hence,  $\beta$ -catenin/TCF4 signaling induces local regulatory DC and regulatory T-cell phenotypes via the RA pathway, identifying this pathway as an important target for anticancer immunotherapy. *Cancer Res*; 75(4); 656–665. ©2015 AACR.

## Introduction

Tumors promote immune tolerance, and dendritic cells (DC) play an important role in this. Although the molecular mechanisms of immune suppression by DCs are not fully understood, the ability of DCs to induce and activate regulatory T cells (Treg) is involved (1–5). Retinoic acid (RA), an active metabolite of vitamin A, regulates a broad array of immune responses (6, 7). Accumulated evidence suggests an important role for RA in immune tolerance in the gut by regulating the functions of antigen-presenting cells (APC), and by promoting the induction and activation of Treg (6, 7). A recent study has shown that tumor microenvironment (TME) contains high levels of RA, and APCs are major producers of RA (8). However, its role in Treg induction and activation in response to tumor-induced immune tolerance is not known. Moreover, molecular mechanisms whereby tumors induce APCs to produce RA remain poorly understood. So, we

hypothesized that tumors, through DCs, exploit the RA pathway as a mechanism of immune evasion.

$\beta$ -Catenin is a transcriptional cofactor that, upon activation, interacts with several family transcription factors, such as T-cell factors (TCF; ref. 9), PPAR $\gamma$  (10, 11), Foxo (12, 13), vitamin D receptor (VDR; refs. 12, 14), IRF3 (15), etc. Upon interaction with transcription factors,  $\beta$ -catenin can either promote or suppress the expression of target genes (9, 13, 14). Aberrant  $\beta$ -catenin signaling is associated with cancer development, progression, and even metastasis (9, 16, 17). A recent study has demonstrated that tumors activate  $\beta$ -catenin in APCs including DCs (18). However, its role in the induction and activation of Treg responses to tumor is not known. In addition, the downstream mediator of  $\beta$ -catenin signaling in DCs that drives immune tolerance to tumors remains poorly understood. In our previous study with intestinal DCs, we have shown that the  $\beta$ -catenin pathway programs DCs to a regulatory state and promotes immune tolerance to commensal microbiota (19). So, we hypothesize that tumors promote immune tolerance by activating the  $\beta$ -catenin/TCF pathway in DCs to induce RA, which drives regulatory T-cell responses.

In this study, using murine tumor models, we show that tumors program DCs to produce RA, which promotes immune suppression by inducing regulatory T-cell responses. This is mediated through the induction of vitamin A-metabolizing enzymes via the  $\beta$ -catenin/TCF pathway in DCs, which in turn drives regulatory T-cell responses and suppresses T-cell effector response.

## Materials and Methods

### Mice

C57BL/6 male mice of 6- to 12 weeks of age were purchased from The Jackson Laboratory. OT-II (Rag 2<sup>-/-</sup>) mice were purchased from Taconic. TCF/lymphoid enhancer factor (LEF)-reporter mice (20),  $\beta$ -catenin-flxed mice (21), and CD11c-cre

<sup>1</sup>Cancer Immunology, Inflammation, and Tolerance Program, GRU Cancer Center, Georgia Regents University, Augusta, Georgia. <sup>2</sup>Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. <sup>3</sup>Department of Medicine, Medical College of Georgia, Georgia Regents University, Augusta, Georgia. <sup>4</sup>Department of Microbiology, University of Chicago, Chicago, Illinois. <sup>5</sup>Department of Pediatrics, Medical College of Georgia, Georgia Regents University, Augusta, Georgia.

**Note:** Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Y. Hong and I. Manoharan contributed equally to this article.

**Corresponding Author:** Santhakumar Manicassamy, Georgia Regents University, 1120 15th Street, CN 4153, Augusta, GA 30912. Phone: 706-721-7902; Fax: 706-721-8732; E-mail: smanicassamy@gru.edu

doi: 10.1158/0008-5472.CAN-14-2377

©2015 American Association for Cancer Research.

(22) mice were originally obtained from The Jackson Laboratory and bred on-site. β-Catenin-floxed mice were crossed with transgenic mice expressing Cre recombinase under the control of a CD11c promoter, to generate mice lacking β-catenin in DCs (β-cat<sup>ΔDC</sup>). Successful cre-mediated deletion was confirmed by PCR and protein expression analyses as previously described (19). TCF4-floxed mice (23) were crossed to CD11c-cre mice to generate mice with DCs deficient in TCF4 (TCF4<sup>ΔDC</sup>), and successful cre-mediated deletion was confirmed by PCR (19). All the mice were housed under specific pathogen-free conditions in the Laboratory Animal Services of Georgia Regents University. Animal care protocols were approved by the Institutional Animal Care and Use Committee of Georgia Regents University.

#### Antibodies and reagents

Antibodies against mouse CD4 (GK1.5), CD8a (53-6.7), CD45 (30-F11), Foxp3 (clone FJK-16s), IL10 (JES5-16E3), CD11c (clone N418), I-A<sup>b</sup> (clone 25-9-17), CD90.1 (HIS51), V alpha 2 TCR (B20.1), V beta 5.1/5.2 TCR (MR9-4), IFNγ (XMG1.2), CD80 (16-10A1), CD86 (GL1), CD274 (MH5), and CD273 (TY25) were purchased from eBioscience. Nonphospho active β-catenin, β-catenin, and TCF4 antibodies were obtained from Cell Signaling Technology. β-Galactosidase (β-gal) antibody was purchased from Abcam. Retinol, all-trans retinoic acid (ATRA; Sigma-Aldrich), retinoid acid receptor antagonists LE135 (Tocris), LE540 (Wako), Citral (Sigma-Aldrich), JW55 (Tocris), and XAV 939 (Tocris) were dissolved in DMSO (1 mmol/L). OVA<sub>323-339</sub> (ISQVHAAHAEINEAGR) peptide was purchased from Anaspec.

#### Plasmids, cell culture, transient transfection, and reporter assay

*Raldh2* promoter luciferase construct was kindly provided by Dr. Ofelia M. Martínez-Estrada (24). Wild-type (WT) β-catenin, dominant-negative β-catenin, and active β-catenin plasmids were provided by Dr. Zuoming Sun (City of Hope). WT-TCF4 and dominant-negative TCF4 plasmids were from Addgene. 293T cells were cultured in DMEM supplemented with 10% FBS, 2 mmol/L glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells (2–3 × 10<sup>5</sup> in each well of a 24-well plate) were transfected with the *Raldh2* promoter reporter plasmid (100 ng) and expression vectors (500 ng) by the Lipofectamine method (Invitrogen). The total amount of transfected DNA was kept constant by adjusting the amount of the empty vector. Cells were collected after 24 hours and lysed in 200 μL reporter lysis buffer, and luciferase activities were measured by the Luciferase system, according to the manufacturer's instructions (Promega), and normalized against *Renilla* luciferase activities. "Fold Induction" represents normalized luciferase activity divided by the result of reporter-only groups.

#### Tumor model and *in vivo* treatment

Age-matched littermate control mice were used for tumor studies. B16 melanoma expressing ovalbumin, clone MO4, was obtained from Dr. David Munn (Georgia Regents University, Augusta, GA; ref. 25), and EL4 lymphoma expressing ovalbumin, clone E.G7-OVA (EG7), was obtained from the American Type Culture Collection. To establish tumors, 5 × 10<sup>5</sup> MO4 and EG7 cells were injected s.c. into mice in the shaved flank region. The tumor growth was monitored every 3 days by measuring the perpendicular diameters. The experiments were terminated when

tumor size reached area greater than 2 cm<sup>2</sup>. The tumors were excised, and tumor-draining lymph nodes (TDLN) were collected for various analyses. To study the effect of disulfiram, ATRA, JW55, and XAV 939 *in vivo*, tumor transplanted C57BL/6 or β-catenin<sup>ΔDC</sup> or respective littermate control mice were injected i.p. with disulfiram (5 mg/kg) or ATRA (2.5 mg/kg), JW55 (2 mg/kg), or XAV 939 (2 mg/kg) every 3 days on days 5, 8, 11, and 14 after tumor implantation. Alternatively, mice were treated from day 10 followed by days 13, 16, and 19 after tumor transplantation with XAV939 or with citral (2 mg/mL) in water from day 5 after tumor implantation until day 17 after tumor inoculation. In some experiments, tumor-bearing mice were administered with these treatments, and on day 9, 4 × 10<sup>6</sup> sorted CD4<sup>+</sup>CD25<sup>-</sup>T cells from Rag<sup>-/-</sup> OT-II TCR transgenic mice were injected by i.v. route. Five days later, tumors and TDLNs were removed and stained with antibodies and analyzed by flow cytometry.

#### Cell cultures

CD45<sup>+</sup>CD11c<sup>+</sup> cells from TDLN or tumor were isolated by FACS sorting and cocultured with naïve OT-II (CD4<sup>+</sup>CD25<sup>-</sup>) T cells in the presence of OVA peptide (2 μg/mL), TGFβ (1 ng/mL), and IL2 (5 ng/mL). After 5 days, cells were stained and analyzed for CD4 and Foxp3 expression. In some experiments, purified CD11c<sup>+</sup> DCs (2 × 10<sup>4</sup>) cells were treated with disulfiram (Sigma-Aldrich; 100 nmol/L), retinol (500 nmol/L), ATRA (50 nmol/L), or LE135/LE540 (1 μmol/L) as described in our previous study (26) and followed by coculture with naïve CD25<sup>-</sup>CD4<sup>+</sup> OT-II T cells (1 × 10<sup>5</sup>) in 200 μL RPMI complete medium containing OVA peptide (2 μg/mL) and TGFβ (1 ng/mL) in 96-well round-bottomed plates. After 5 days, cells were collected and analyzed by flow cytometry.

#### Flow cytometry analysis

To measure cytokines, single-cell suspensions from spleen, TDLN, or tumor were *ex vivo* stimulated with phorbol 12-myristate 13-acetate (PMA)/Ionomycin and Brefedina/moesin (eBioscience) for 6 hours at 37°C, and intracellular staining of IFNγ and IL10 was performed. To measure Treg or β-catenin or β-gal expression, corresponding Abs were added after permeabilization and fixation of cells (27). To detect aldehyde dehydrogenase (ALDH) activity, we used the ALDEFUOR Kit (Stemcell) following the manufacturer's recommendations (27). Flow cytometric analysis was performed using a FACS LSRII system (BD Biosciences), and the data were analyzed using FlowJo software.


#### Real-time PCR

Total mRNA was isolated from purified splenic, lymph node, and tumor CD11c<sup>+</sup> DCs using the Omega Total RNA Kit according to the manufacturer's protocol. cDNA was generated using the RNA to cDNA Ecodry Premix Kit (Clontech) according to the manufacturer's protocol. cDNA was used as a template for quantitative real-time PCR using SYBR Green Master Mix (Roche) and gene-specific primers (19, 26). PCR analysis was performed using a MyiQ5 ICycler (BioRad). Gene expression was calculated relative to *Gapdh*.

#### Statistical analyses

Statistical analyses were performed using GraphPad Prism software. An unpaired one-tailed Student *t* test was used to



**Figure 2.**

RA in TME induces Foxp3<sup>+</sup> Tregs. A and B, CD11c<sup>+</sup> DCs were sorted from TDLNs and CLNs of MO4 tumor-bearing WT mice on days 9 to 11 after tumor inoculation and were treated with or without disulfiram (1  $\mu$ M). After 3 hours, DCs were washed and cocultured with CD4<sup>+</sup>CD25<sup>-</sup> cells from Rag2<sup>-/-</sup> OTII mice in RPMI1640 medium containing OVA peptide (2  $\mu$ g/mL) and TGF $\beta$  (1 ng/mL), in the presence or absence of LE540+LE135 (1  $\mu$ M) or retinol (1  $\mu$ M) or ATRA (5 nmol/L) combination for 5 days. Representative FACS plots (A) and frequencies (B) of Foxp3<sup>+</sup>CD4<sup>+</sup> T ( $n = 3$ ; DCs were pooled from 5 to 6 mice, and experiment was repeated at least two times). C, *ex vivo* analysis of ALDH activity in CD11c<sup>+</sup> DCs enriched from TDLNs, CLNs, and tumors from WT mice treated with or without disulfiram on day 14 after tumor inoculation. DEAB, a specific inhibitor of ALDH, was used as control for background fluorescence. Data shown are representative histograms gated on CD45<sup>+</sup>CD11c<sup>+</sup> cells from one experiment of two independent experiments. DCs were pooled from 5 to 6 tumor-bearing mice for each experiment. D and E, MO4-bearing mice treated with or without disulfiram were adoptively transferred with OT-II T cells from Rag2<sup>-/-</sup>OTII mice on day 9 after tumor inoculation. After 5 days, FACS analysis was performed on CD45<sup>+</sup> $\alpha$ 2<sup>+</sup>V $\beta$ 5.1/5.2<sup>+</sup>CD4<sup>+</sup> T cells from TDLNs and tumor tissues. D, data shown are percentage and representative dot plots of OVA-specific Foxp3<sup>+</sup>CD4<sup>+</sup> T cells ( $n = 3$  to 4 mice per experiment. Experiment was repeated two times). E, data are from experiment D, showing cumulative frequencies of adoptively OVA-specific Foxp3<sup>+</sup>CD4<sup>+</sup> T cells and showing mean values  $\pm$  SEM ( $n = 6$  to 8 mice). F, percentage of endogenous Foxp3<sup>+</sup>CD4<sup>+</sup> Treg cells in tumors isolated from WT mice treated with or without disulfiram ( $n = 5$  mice). Error bars, mean values  $\pm$  SEM. Statistical levels of significance were analyzed by the Student *t* test (unpaired) \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .


with disulfiram significantly decreased the Aldh1 activity in TDLN DCs as compared with untreated control group (Fig. 2C). In addition, disulfiram treatment of tumor-bearing mice significantly delayed tumor growth in mice compared with control mice (Supplementary Fig. S1A). Next, we analyzed the differences in frequency of Foxp3<sup>+</sup> OT-II T cells treated with or without disulfiram. Blocking Aldh1 activity markedly reduced the frequency of induced Tregs both in TDLN and in tumor tissue compared with untreated mice (Fig. 2D and E). Moreover, disulfiram treatment also affected the frequency of endogenous Tregs within the tumor (Fig. 2F). These findings were further confirmed with citral, another

Aldh1 inhibitor (Supplementary Fig. S1B and S1C; ref. 29). These observations demonstrate that pharmacologic blocking of vitamin A-metabolizing enzyme suppresses Treg differentiation and enhances antitumor immunity. Thus, RA is necessary for *in vivo* induction of Tregs in response to tumors.

#### $\beta$ -Catenin/TCF4 is critical for the expression of vitamin A-metabolizing enzymes in DCs

Recent studies have shown that tumors activate  $\beta$ -catenin in immune cells including DCs (18, 30). Our previous study on intestinal DCs has shown that Aldh1a1 and Aldh1a2 are

Hong et al.

**Figure 3.**

$\beta$ -Catenin/TCF4 pathway induces vitamin A-metabolizing enzymes in DCs. A, representative histograms showing active  $\beta$ -catenin (left) and  $\beta$ -catenin (right) expression in CD11c<sup>+</sup> cells from MO4 tumor TDLN and CLN of tumor-free C57BL/6 (WT) mice on day 9 after tumor inoculation. B and C, real-time PCR analysis of *Aldh1a2* expression from TDLNs, CLNs, and tumors ( $n = 3$ ); B) and *ex vivo* analysis of ALDH activity in CD11c<sup>+</sup> DCs enriched from TDLNs from  $\beta$ -cat<sup>ADC</sup> and control-FL mice (C). D, representative histograms showing  $\beta$ -gal expression in CD11c<sup>+</sup> cells from TDLNs and CLNs of *TCF/LEF-LacZ* reporter mice. E, *Axin2* mRNA expression analyzed by qRT-PCR in TDLNs and CLNs on day 9 after inoculation ( $n = 4$ ). The result represents fold increase over the CLNs. F, *Aldh1a2* promoter activity in 293T cell after 24-hour transfection reporter plasmid alone or cotransfection with WT- $\beta$ -catenin (WT- $\beta$ cat), dominant-negative  $\beta$ -catenin (DN- $\beta$ cat), active  $\beta$ -catenin (CA- $\beta$ cat), WT-TCF4, or dominant-negative TCF4 (DN-TCF4) expression vectors. The results are represented as fold activation relative to *Aldh1* promoter vector transfection control alone. G, real-time PCR analysis of *Aldh1a2* expression in CD11c<sup>+</sup> DCs enriched from TDLNs, CLNs, and tumors from TCF4<sup>ADC</sup> and control-FL mice. Iso, isotype control. DCs were enriched and pooled from 5 to 6 tumor-bearing mice (A, C, and D). Each sample was done in triplicate; the average and SD are shown. The experiment was repeated at least two (B, E, and G) or three (F) times with similar results. Error bars, mean values  $\pm$  SEM. Statistical levels of significance were analyzed by the Student *t* test (unpaired) \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

$\beta$ -catenin target genes (19). We hypothesized that tumor-induced activation of the  $\beta$ -catenin pathway in DCs is critical for upregulation of RA-synthesizing enzymes. So, we assessed whether tumors activate  $\beta$ -catenin in DCs using an antibody that recognizes the active form of  $\beta$ -catenin. Consistent with a previous study (18), TDLN DCs showed increased levels of active  $\beta$ -catenin compared with CLN DCs or isotype control (Fig. 3A, right plot). However, both CLN DCs and TDLN DCs expressed a similar level of total  $\beta$ -catenin (Fig. 3A, left plot), suggesting that tumors induce the activation of  $\beta$ -catenin in DCs but do not affect its expression. Next, we examined whether induction of Aldh1 in TDLN DCs is dependent on the activation of  $\beta$ -catenin. In contrast with TDLN DCs from control-FL mice, DCs deficient in  $\beta$ -catenin (19) expressed significantly lower levels of Aldh1 in response to MO4 and EG7 tumors (Fig. 3B; Supplementary Fig. S2). Consistent with this observation,  $\beta$ -catenin-deficient TDLN DCs showed markedly reduced Aldh1 activity compared with respective control-FL TDLN DCs (Fig. 3C). Collectively, these data demonstrate that TME programs DCs to express Aldh1a2 in a  $\beta$ -catenin-dependent manner.

We next investigated the downstream signaling pathways through which  $\beta$ -catenin can induce Aldh1 expression in DCs. The TCF family of transcription factors is one of the main downstream mediators of  $\beta$ -catenin signaling (9), and DCs highly express the TCF4 isoform (31). So, we tested whether tumor-induced activation of  $\beta$ -catenin in DCs promotes *TCF/LEF*-dependent gene transcription using *TCF/LEF*  $\beta$ -gal reporter mice (19). TDLN DCs from the reporter mice showed strong  $\beta$ -gal expression compared with CLN DCs (Fig. 3D). Consistent with this, we also observed increased expression of the  $\beta$ -catenin/TCF4 target gene, *Axin2*, in TDLN DCs compared with CLN DCs (Fig. 3E). Taken together, our data demonstrate that activation of  $\beta$ -catenin induces the expression of *TCF4* target genes in DCs in response to tumor.

Based on the above observation, we reasoned that TCF4 is the downstream mediator of  $\beta$ -catenin signaling in DCs that drives the expression of RA-synthesizing enzymes in response to tumor. Promoter analysis using consensus TCF-binding sites showed several potential TCF sites in the *Aldh1a2* promoter region with some near the transcription initiation regions. To further investigate transcriptional


regulation of *Aldh1a2* by  $\beta$ -catenin/TCF4, 293T cells were stably transfected with a 830-bp *Aldh1a2*-promoter luciferase reporter plasmid (24) either alone or in combination with WT or mutant  $\beta$ -catenin or TCF4 expression plasmids. Cotransfection with WT  $\beta$ -catenin and WT-TCF4 plasmids resulted in 10- to 12-fold increase of *Aldh1a2* promoter activity (Fig. 3F). Likewise, expression of active  $\beta$ -catenin further increased promoter activity. In contrast, expression of a dominant-negative  $\beta$ -catenin or TCF4 markedly decreased its activity (Fig. 3F). Consistent with these observations, deletion of TCF4 specifically in DCs resulted in decreased expression of *Aldh1a2* gene in response to tumor (Fig. 3G). Taken together, these results clearly demonstrate that TME induces expression of activated  $\beta$ -catenin in DCs, which interacts with TCF4 and promotes transcriptional activation of *Aldh1* gene expression.

#### DC-specific deletion of $\beta$ -catenin limits regulatory T-cell induction and tumor growth

The preceding experiments showed that tumor-associated DCs produce RA and drive regulatory T-cell differentiation. So, we hypothesized that tumor-induced activation of the  $\beta$ -catenin/TCF pathway in DCs induces regulatory T-cell responses and promotes immune tolerance. To test this, we monitored MO4 and EG7 tumor growth over time in mice that specifically lack  $\beta$ -catenin in DCs (19). Deletion of  $\beta$ -catenin in DCs ( $\beta$ -cat<sup>ADC</sup>) significantly reduced tumor growth compared with that seen with WT mice (Fig. 4A and


B). Next, we examined the effector phenotype of tumor-infiltrating lymphocytes isolated from both groups of mice. Interestingly, we observed a significant decrease in the frequency of Foxp3<sup>+</sup>CD4<sup>+</sup> Tregs, IL10<sup>+</sup>CD4<sup>+</sup> Tr1 cells, and IL10<sup>+</sup>CD8<sup>+</sup> T cells in tumors of  $\beta$ -cat<sup>ADC</sup> mice compared with controls (Fig. 4C and D). In contrast, melanomas isolated from  $\beta$ -cat<sup>ADC</sup> mice contained a higher frequency of IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup> and IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells compared with melanomas of control mice (Fig. 4E and F). These findings were further confirmed with EG7 tumor (Supplementary Fig. S3A). Collectively, these results show that tumor-mediated activation of  $\beta$ -catenin in DCs promotes regulatory T-cell responses and limits antitumor immunity.

Next, we wished to test whether enhanced antitumor immunity and reduced regulatory T-cell responses observed in  $\beta$ -cat<sup>ADC</sup> mice are due to changes in DC maturation or activation. Phenotypic characterization of TDLN CD11c<sup>+</sup> DCs from  $\beta$ -cat<sup>ADC</sup> mice expressed greatly enhanced levels of the activation markers CD80 and CD86, and reduced levels of coinhibitory molecules such as PDL1 and PDL2. These observations suggest that the  $\beta$ -catenin pathway also regulates the activation status of DCs. However, we observed similar levels of MHC class II expression in TDLN CD11c<sup>+</sup> DCs isolated from WT and  $\beta$ -cat<sup>ADC</sup> mice (Supplementary Fig. S3B). This observation is consistent with previous studies suggesting that the  $\beta$ -catenin pathway is not critical for DC maturation (27, 32, 33). Taken together, these results show that tumor-mediated activation of  $\beta$ -catenin in DCs limits antitumor immunity at least in part



**Figure 4.** DC-specific deletion of  $\beta$ -catenin enhances antitumor immunity in mice. A, MO4 melanoma progression in  $\beta$ -cat<sup>ADC</sup> and control-FL mice ( $n = 10$ -12). B, EG-7 tumor progression in  $\beta$ -cat<sup>ADC</sup> and control-FL mice ( $n = 6$ -8). C-F, representative dot plots and percentages of IL10<sup>+</sup>CD4<sup>+</sup>, Foxp3<sup>+</sup>CD4<sup>+</sup>, IL10<sup>+</sup>CD8<sup>+</sup>, IFN $\gamma$ <sup>+</sup>CD4<sup>+</sup>, and IFN $\gamma$ <sup>+</sup>CD8<sup>+</sup> T cells isolated from MO4 melanoma in control-FL and  $\beta$ -cat<sup>ADC</sup> mice on day 14 after inoculation ( $n = 5$  to 6 mice). Data are representative of two independent experiments and show mean values  $\pm$  SEM. Statistical levels of significance were analyzed by the Student  $t$  test (unpaired). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

Hong et al.

**Figure 5.**

Loss of  $\beta$ -catenin impairs DCs ability to induce Tregs differentiation, and ATRA treatment can restore it. A, CD11c<sup>+</sup> cells were sorted from CLNs (top) and TDLNs (bottom) of MO4 tumor-bearing  $\beta$ -cat<sup>ADC</sup> and control-FL mice and were cocultured with CD4<sup>+</sup>CD25<sup>-</sup> naive T cells as described in Fig. 2A. Data are shown as percentage and representative dot plots of Foxp3<sup>+</sup>CD4<sup>+</sup> T cells of one experiment of two independent experiments (DCs were pooled and enriched from 5 to 6 mice for each experiment). Each sample was done in triplicate. B, *in vivo* OT-II Treg differentiation in  $\beta$ -cat<sup>ADC</sup> and control-FL mice was performed as described in Fig. 2D. Data, cumulative percentage of OVA-specific Foxp3<sup>+</sup>CD4<sup>+</sup> T cells in TDLNs and tumors isolated from  $\beta$ -cat<sup>ADC</sup> and control-FL mice ( $n = 5-6$ ). C, the MO4 melanoma progression in  $\beta$ -cat<sup>ADC</sup> mice treated with or without ATRA (2.5 mg/kg) every 3 days from day 1 after tumor inoculation. Data, mean tumor size and are cumulative, representative of two independent experiments  $\beta$ -cat<sup>ADC</sup> versus  $\beta$ -cat<sup>ADC</sup> + ATRA ( $n = 6-8$  mice; combined results of two independent experiments are shown). D, *in vivo* OT-II Treg differentiation in  $\beta$ -cat<sup>ADC</sup> treated with or without ATRA was performed as described in Fig. 2D. Percentage of OVA-specific Foxp3<sup>+</sup>CD4<sup>+</sup> Tregs and endogenous Foxp3<sup>+</sup>CD4<sup>+</sup> Tregs in TDLNs and tumors isolated from  $\beta$ -cat<sup>ADC</sup> and control-FL mice treated with or without ATRA ( $n = 6$  to 8 mice). Data, two independent experiments and show mean values  $\pm$  SEM. Statistical levels of significance were analyzed by the Student *t* test (unpaired). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

by regulating the expression levels of coinhibitory and costimulatory molecules.


#### Tumor promotes regulatory DCs via a $\beta$ -catenin/RA axis

The preceding results demonstrated that activation of  $\beta$ -catenin in DCs promotes regulatory T-cell response and limits T-cell effector response. So, we reasoned that tumor-induced activation of the  $\beta$ -catenin pathway imparts regulatory phenotype on DCs and promotes regulatory T-cell response. Therefore, we tested the ability of TDLN DCs isolated from control-FL and  $\beta$ -cat<sup>ADC</sup> mice to promote differentiation of naive CD4<sup>+</sup> T cells into Foxp3<sup>+</sup> Tregs. TDLN DCs from control-FL mice induced a higher frequency of Foxp3<sup>+</sup> Tregs compared with CLN DCs (Fig. 5A). In contrast, TDLN DCs from  $\beta$ -cat<sup>ADC</sup> mice induced a lower frequency of Foxp3<sup>+</sup> Tregs compared with control TDLN DCs (Fig. 5A).

To extend these observations *in vivo*, we implanted MO4 melanoma cells in control-FL and  $\beta$ -cat<sup>ADC</sup> mice, and on day 9, naive OT-II CD4<sup>+</sup> T cells were adoptively transferred as shown in Fig. 5B. Consistent with *in vitro* results, the frequency of induced OVA-specific Foxp3<sup>+</sup>CD4<sup>+</sup> Tregs was markedly reduced both in TDLN and in tumors of  $\beta$ -cat<sup>ADC</sup> mice com-

pared with control mice in response to tumor burden (Fig. 5B). Altogether, these data demonstrate that tumor-induced activation of  $\beta$ -catenin in DCs imparts regulatory phenotype and drives Treg differentiation.

The above results show that deletion of  $\beta$ -catenin in DCs results in loss of regulatory phenotype and limits DCs ability to drive Treg induction. Moreover, these DCs express low levels of RA-synthesizing enzymes. Therefore, we hypothesized that exogenous delivery of RA would promote regulatory T-cell differentiation and restore the tumor growth in  $\beta$ -cat<sup>ADC</sup> mice. To test this, we challenged these mice with MO4 cells and then treated them with RA. As expected, tumor growth in the  $\beta$ -cat<sup>ADC</sup> mice was delayed and lagged behind tumor growth seen with control mice (Fig. 5C). In contrast, RA treatment of  $\beta$ -cat<sup>ADC</sup> mice accelerated tumor growth compared with the untreated mice (Fig. 5C). We then asked whether this accelerated tumor growth is associated with an increase in endogenous as well as antigen-specific Tregs. Injection of OT-II CD4<sup>+</sup> T cells into RA-treated  $\beta$ -cat<sup>ADC</sup> tumor-bearing mice resulted in increased frequency of OVA-specific Foxp3<sup>+</sup> CD4<sup>+</sup> Tregs within tumors (Fig. 5D). We also observed marked increase in the frequency of endogenous Foxp3<sup>+</sup> CD4<sup>+</sup> Tregs within tumors (Fig. 5D). These data suggest that RA can induce Tregs and promote

**Figure 6.**

Therapeutic effect of blocking the  $\beta$ -catenin pathway against established tumors. The MO4 melanoma progression in WT mice treated with or without XAV 939 (2 mg/kg) every 3 days from day 5 after tumor inoculation. A, data are mean tumor size and are cumulative, representative of two independent experiments ( $n = 10$ – $12$  mice; data show combined results of two independent experiments with 5 to 6 mice per experiment). B and C, representative dot plots and percentage of  $\text{IFN}\gamma^+\text{CD4}^+$ ,  $\text{IFN}\gamma^+\text{CD8}^+$ , and  $\text{Foxp3}^+\text{CD4}^+$  T cells isolated from MO4 on day 20 after inoculation. D and E, *in vivo* OT-II Treg differentiation in WT mice treated with or without XAV 939 was performed as described in Fig. 2D. Data are representative dot plots (D) and cumulative percentage (E) of induced OVA-specific  $\text{Foxp3}^+\text{CD4}^+$  Tregs isolated from TDLN and tumor ( $n = 5$  to 6 per sample). Data are representative of two independent experiments and show mean values  $\pm$  SEM. Combined results of two separate experiments are shown, with 5 to 6 mice per group in each experiment. F, real-time PCR analysis of *Aldh1a2* expression in  $\text{CD11c}^+$  DCs enriched from TDLNs from WT mice treated with or without XAV 939. Each sample was done in triplicate; the average and SD are shown. The experiment was repeated two times with similar results. Statistical levels of significance were analyzed by the Student *t* test (unpaired). \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .

tumor growth, further emphasizing the contribution of the  $\beta$ -catenin/TCF4-RA axis in immune tolerance to tumors.

#### Pharmacologic inhibition of the $\beta$ -catenin/TCF pathway impairs regulatory T-cell induction and enhances antitumor immunity

To explore the above findings in a clinically relevant model, we examined the effects of pharmacologic inhibition of the  $\beta$ -catenin/TCF pathway with the tankyrase inhibitor, XAV 939 (34). Accordingly, treatment of melanoma or EG7 tumor-bearing WT mice with XAV 939 delayed tumor growth compared with untreated mice (Fig. 6A; Supplementary Fig. S4A). In addition, therapeutic treatment of mice with XAV 939 at day 10 after tumor transplantation, when the tumor volume is greater, also delayed the tumor growth (Supplementary Fig. S4B). Consistent with the reduced tumor growth, XAV 939 treatment resulted in significant decrease in numbers of Tregs and an increase in the frequencies of  $\text{IFN}\gamma^+\text{CD4}^+$  and  $\text{IFN}\gamma^+\text{CD8}^+$  effector T cells infiltrating the tumor (Fig. 6B and C; Supplementary Fig. S4C). Furthermore, the ratio of effector T cells to Tregs was markedly increased within the tumor of treated mice compared with the control mice (data not shown).

Consistent with this observation, XAV 939 treatment of tumor-bearing mice that had received OT-II  $\text{CD4}^+$  T cells by adoptive transfer resulted in the decrease in frequency and number of OVA-specific Tregs within tumors (Fig. 6D and E). Consistent with the reduced Treg induction, XAV 939 treatment markedly reduced the expression of vitamin A-metabolizing enzymes (Fig. 6F; Supplementary Fig. S4D). We confirmed these findings in using another  $\beta$ -catenin/TCF inhibitor, JW55 (35, 36; Supplementary Fig. S5). Collectively, these data demonstrate that blocking the  $\beta$ -catenin/TCF4 pathway suppresses Treg differentiation and enhances antitumor immunity.

#### Discussion

Tumors actively suppress immune responses, and this represents a fundamental barrier to cancer immunotherapy. DCs are important in this process, but the molecular mechanisms of immune suppression by DCs are not fully understood. The current study demonstrates for the first time that RA in the TME directly drives immune suppression by inducing regulatory T-cell responses. A key mechanism of this is through induction of vitamin A-metabolizing enzymes in DC via the  $\beta$ -catenin/TCF



Hong et al.

pathway, which in turn drives regulatory T-cell responses and suppresses T effector cell response. Pharmacologic intervention of vitamin A–metabolizing enzyme activity or the  $\beta$ -catenin/TCF pathway limits regulatory T-cell responses and enhances antitumor immunity. Collectively, these findings support the hypothesis that tumors induce DCs to produce RA by activating the  $\beta$ -catenin/TCF4 pathway, thereby promoting immune tolerance. Hence, this pathway constitutes a new target for cancer immunotherapy. Several aspects of these findings deserve further comment.

First, the role of RA in the induction of Tregs in the intestine and gut tolerance has been extensively studied (6, 7). However, its role in tumor-induced immune tolerance is poorly understood. TME has high levels of RA, and APCs are major producers of RA (8). Also, the signaling pathways that promote DCs to metabolize vitamin A into RA are not known. Our studies demonstrate that DCs in the TME acquire the ability to metabolize vitamin A via the activation of the  $\beta$ -catenin/TCF4 pathway, which programs them to promote regulatory T-cell responses. RA acts directly on CD4 cells inducing regulatory T-cell responses and suppresses T effector cell response. Deletion of  $\beta$ -catenin or TCF-4 in DCs resulted in significant decrease in Aldh1 expression, and these DCs were less potent in inducing Tregs in response to melanoma. Consistent with this observation, pharmacologic inhibition of Aldh1 activity significantly delayed tumor growth and enhanced the antitumor immunity. In addition to inducing Tregs, recent studies indicate that RA can also act directly on DCs imparting regulatory phenotype via induction of SOCS3 (26, 37).

Second, aberration in the  $\beta$ -catenin/TCF signaling pathway is associated with poor prognosis in many human tumors, but the focus of most research has been on the effects of this pathway on the tumor cells themselves (16, 38, 39). In models of gut tolerance, our previous studies have shown that  $\beta$ -catenin signaling in DCs programs them into a regulatory state and promotes regulatory T-cell responses (19, 32, 40); however, whether this pathway promotes immune suppression in tumors was not known. The present study clearly demonstrates that tumor-induced activation of the  $\beta$ -catenin/TCF4 pathway programs DCs into an immunosuppressive state and promotes immune tolerance. TME can also modulate DC function by regulating DC activation and maturation, by regulating the expression of costimulatory and coinhibitory molecules. Our study shows that deletion of  $\beta$ -catenin resulted in increased expression of costimulatory molecules and decreased expression of coinhibitory molecules. This phenotype is associated with DC in an immunogenic state, resulting in enhanced antitumor immunity. In addition to inducing Tregs,  $\beta$ -catenin activation in DCs can also affect cross priming of CD8 T-cell responses against tumors (18). Although  $\beta$ -catenin is known to suppress DC activation (7), it remains to be determined whether  $\beta$ -catenin directly regulates DC activation or does so indirectly via RA.

The receptor(s) on DCs or factor(s) in TME that activate  $\beta$ -catenin in DCs are currently not known. Emerging studies show that TME contains high levels of Wnt ligands (16, 38, 39), TGF $\beta$  (41), and TLR ligands (42). These molecules can also initiate signaling within DCs to activate the  $\beta$ -catenin pathway, to promote immune suppression. The role of these molecules if any in the activation of  $\beta$ -catenin

pathway in DCs in TME is currently unknown. In addition, the downstream mediator of  $\beta$ -catenin signaling in DCs was not known. The present study shows that TCF4 is one of the key mediators of  $\beta$ -catenin signaling in DCs in TME. Upon activation,  $\beta$ -catenin is known to interact with other transcription factors such as PPAR $\gamma$  (10, 11), Foxo (12, 13), VDR (12, 14), and IRF3 (15), which are known regulators of immune responses, but additional studies will be required to determine the role of  $\beta$ -catenin in the regulation of these transcription factors and their target genes in response to antitumor immunity.

Other regulatory factors such as indoleamine 2,3-dioxygenase (IDO), IL10, and TGF $\beta$ , though not analyzed in present study, may play a role in tumor tolerance through the  $\beta$ -catenin/TCF pathway (3, 26, 40–42). The present study was focused on RA because blocking RA essentially recapitulated the effects of a conditional knockout of  $\beta$ -catenin in mice. Furthermore, exogenous addition of RA fully restored tumor growth and immune suppression in  $\beta$ -catenin conditional knockout mice. Thus, our data indicate that signaling initiated by the  $\beta$ -catenin/TCF4 pathway in DCs promotes both tumor growth and immune suppression.

In summary, our study reveals a novel mechanistic link between the  $\beta$ -catenin/TCF pathway in DCs, RA, and Tregs, by which tumors promote immune tolerance. The present data demonstrate that pharmacologic disruption of this pathway altered DC function, resulting in enhanced immune response against established tumors. These findings have important implications for tumor immunotherapy, suggesting that blocking the  $\beta$ -catenin pathway in DCs helps the goal of breaking tumor-induced immune suppression by enhancing antitumor immunity against established tumors.

### Disclosure of Potential Conflicts of Interest

A.L. Mellor has ownership interest (including patents) and is a consultant/advisory board member for NewLink Genetics. No potential conflicts of interest were disclosed by the other authors.

### Authors' Contributions

**Conception and design:** Y. Hong, I. Manoharan, D.H. Munn, S. Manicassamy  
**Development of methodology:** Y. Hong, A. Suryawanshi, T. Majumdar, S. Manicassamy

**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** Y. Hong, I. Manoharan, M.L. Angus-Hill, S. Manicassamy

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** Y. Hong, I. Manoharan, A. Suryawanshi, D.H. Munn, S. Manicassamy

**Writing, review, and/or revision of the manuscript:** Y. Hong, I. Manoharan, A. Suryawanshi, T. Majumdar, M.L. Angus-Hill, P.A. Koni, A.L. Mellor, S. Manicassamy

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** B. Manicassamy

**Study supervision:** S. Manicassamy

**Other (reviewed the article and provided constructive feedback to the senior author):** A.L. Mellor

### Acknowledgments

The authors thank Jeanene Pihkala and William King for technical help with FACS sorting and analysis, Dr. Madhav Sharma for assistance with mouse tumor models, Janice Randall with mouse husbandry, and Dr. Martinez-Estrada for Raldh2 promoter luciferase construct.

**Grant Support**

This work was supported by NIH awards DK097271 and AI04875 (S. Manicassamy) and GRU Cancer Center Seed Grant.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

*advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 14, 2014; revised November 10, 2014; accepted November 26, 2014; published OnlineFirst January 7, 2015.

**References**

- Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. *Annu Rev Immunol* 2007;25:267–96.
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* 2013;39:1–10.
- Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGF $\beta$ . *Nat Rev Immunol* 2010;10:554–67.
- Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. *J Clin Invest* 2007;117:1147–54.
- Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. *Nat Rev Cancer* 2012;12:265–77.
- Hall JA, Grainger JR, Spencer SP, Belkaid Y. The role of retinoic acid in tolerance and immunity. *Immunity* 2011;35:13–22.
- Manicassamy S, Pulendran B. Retinoic acid-dependent regulation of immune responses by dendritic cells and macrophages. *Semin Immunol* 2009;21:22–7.
- Guo Y, Pino-Lagos K, Ahonen CA, Bennett KA, Wang J, Napoli JL, et al. A retinoic acid-rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells. *Cancer Res* 2012;72:5230–9.
- Reya T, Clevers H. Wnt signalling in stem cells and cancer. *Nature* 2005;434:843–50.
- Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK, et al. Disruption of PPAR $\gamma$ /beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. *J Clin Invest* 2011;121:3735–46.
- Liu J, Wang H, Zuo Y, Farmer SR. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. *Mol Cell Biol* 2006;26:5827–37.
- Hooigeboom D, Essers MA, Polderman PE, Voets E, Smits LM, Burgering BM. Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity. *J Biol Chem* 2008;283:9224–30.
- Yan Y, Lackner MR. FOXO3a and beta-catenin co-localization: double trouble in colon cancer? *Nat Med* 2012;18:854–6.
- Shah S, Islam MN, Dakshanamurthy S, Rizvi I, Rao M, Herrell R, et al. The molecular basis of vitamin D receptor and beta-catenin crossregulation. *Mol Cell* 2006;21:799–809.
- Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, et al. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. *Nat Immunol* 2010;11:487–94.
- Macheda ML, Stacker SA. Importance of Wnt signaling in the tumor stroma microenvironment. *Curr Cancer Drug Targets* 2008;8:454–65.
- Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. *Nat Rev Cancer* 2008;8:387–98.
- Liang X, Fu C, Cui W, Ober-Blobaum JL, Zahner SP, Shrikant PA, et al. beta-catenin mediates tumor-induced immunosuppression by inhibiting cross-priming of CD8(+) T cells. *J Leukoc Biol* 2014;95:179–90.
- Manicassamy S, Reizis B, Ravindran R, Nakaya H, Salazar-Gonzalez RM, Wang YC, et al. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. *Science* 2010;329:849–53.
- Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, et al. Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. *Proc Natl Acad Sci U S A* 2003;100:3299–304.
- Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, McMahon AP, et al. Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. *Development* 2001;128:1253–64.
- Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-1 signaling controls the homeostasis of CD8- dendritic cells in the spleen. *J Exp Med* 2007;204:1653–64.
- Angus-Hill ML, Elbert KM, Hidalgo J, Capecci MR. T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. *Proc Natl Acad Sci U S A* 2011;108:4914–9.
- Guadix JA, Ruiz-Villalba A, Lettice L, Vecelela V, Munoz-Chapuli R, Hastie ND, et al. Wt1 controls retinoic acid signalling in embryonic epicardium through transcriptional activation of Raldh2. *Development* 2011;138:1093–7.
- Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. *J Clin Invest* 2007;117:2570–82.
- Manicassamy S, Ravindran R, Deng J, Oluoch H, Denning TL, Kasturi SP, et al. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. *Nat Med* 2009;15:401–9.
- Manoharan I, Hong Y, Suryawanshi A, Angus-Hill ML, Sun Z, Mellor AL, et al. TLR2-dependent activation of beta-catenin pathway in dendritic cells induces regulatory responses and attenuates autoimmune inflammation. *J Immunol* 2014;193:4203–13.
- Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *J Clin Invest* 2004;114:280–90.
- Stern A, Wold AE, Ostman S. Neonatal mucosal immune stimulation by microbial superantigen improves the tolerogenic capacity of CD103(+) dendritic cells. *PLoS One* 2013;8:e75594.
- Capietto AH, Kim S, Sanford DE, Linehan DC, Hikida M, Kumosaki T, et al. Down-regulation of PLC $\gamma$ 2-beta-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. *J Exp Med* 2013;210:2257–71.
- Ghosh HS, Cisse B, Bunin A, Lewis KL, Reizis B. Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. *Immunity* 2010;33:905–16.
- Jiang A, Bloom O, Ono S, Cui W, Unteraehrer J, Jiang S, et al. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. *Immunity* 2007;27:610–24.
- Oderup C, Lajevic M, Butcher EC. Canonical and noncanonical Wnt proteins program dendritic cell responses for tolerance. *J Immunol* 2013;190:6126–34.
- Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. *Nature* 2009;461:614–20.
- Waalder J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. *Cancer Res* 2012;72:2822–32.
- Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer* 2013;13:11–26.
- Villablanca EJ, Wang S, de Calisto J, Gomes DC, Kane MA, Napoli JL, et al. MyD88 and retinoic acid signaling pathways interact to modulate gastrointestinal activities of dendritic cells. *Gastroenterology* 2011;141:176–85.
- Huang D, Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. *World J Gastroenterol* 2008;14:1823–7.
- Larue L, Delmas V. The WNT/Beta-catenin pathway in melanoma. *Front Biosci* 2006;11:733–42.
- Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. *Immunol Rev* 2011;241:206–27.
- Jian H, Shen X, Liu I, Semenov M, He X, Wang XF. Smad3-dependent nuclear translocation of beta-catenin is required for TGF-beta1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. *Genes Dev* 2006;20:666–74.
- Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing toll-like receptors and the tumor microenvironment. *Cancer Microenviron* 2009; 2 Suppl 1:205–14.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## $\beta$ -Catenin Promotes Regulatory T-cell Responses in Tumors by Inducing Vitamin A Metabolism in Dendritic Cells

Yuan Hong, Indumathi Manoharan, Amol Suryawanshi, et al.

*Cancer Res* 2015;75:656-665. Published OnlineFirst January 7, 2015.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/0008-5472.CAN-14-2377](https://doi.org/10.1158/0008-5472.CAN-14-2377)

**Supplementary Material** Access the most recent supplemental material at:  
<http://cancerres.aacrjournals.org/content/suppl/2015/01/09/0008-5472.CAN-14-2377.DC1>

**Cited articles** This article cites 42 articles, 14 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/75/4/656.full#ref-list-1>

**Citing articles** This article has been cited by 3 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/75/4/656.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/75/4/656>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.